CME

Guest: Terry J. Smith, MD

Guest: Selina McGee, OD, FAAO

Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

Host: Prem S. Subramanian, MD, PhD

Guest: Selina McGee, OD, FAAO

Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

Guest: Fatemeh Rajaii, MD, PhD

Guest: Terry J. Smith, MD

Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

Host: Prem S. Subramanian, MD, PhD

Guest: Terry J. Smith, MD

Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

Guest: Fatemeh Rajaii, MD, PhD

Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves’ disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

Host: Sara M. Tolaney, MD, MPH

This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to enhance clinical decision-making in the evolving landscape of metastatic breast cancer care.

FDA Approval January 2025:

On January 27, 2025, trastuzumab deruxtecan (T-DXd) was approved by the FDA for patients with HR+, HER2-low or HER2-ultralow unresectable or metastatic breast cancer who have progressed on one or more endocrine therapies in the metastatic setting.

On January 17, 2025, datopotamab deruxtecan (Dato-DXd) was approved by the FDA for patients with HR+/HER2- unresectable or metastatic breast cancer who have received prior endocrine therapy and chemotherapy for unresectable or metastatic disease.

Host: Christina Economides, MD

Guest: Brian Howard, MD

Guest: David N. Kenigsberg, MD, FACC

Despite guideline-directed medical therapy, many patients with heart failure will continue to develop worsening symptoms and diminishing quality of life. Baroflex activation therapy (BAT) may be a treatment option for patients with heart failure with reduced ejection fraction. Data show clinical benefit with this treatment approach including long-term symptom improvement and reduction in all-cause death. To ensure optimal outcomes with BAT, a multidisciplinary approach is necessary. In this activity, expert faculty review the rationale for BAT therapy, the supporting clinical data, the surgical procedure for the BAT device, and best practices for optimizing a multidisciplinary approach.

Host: Amir T. Fathi, MD

Guest: Courtney DiNardo, MD

Guest: Brian A. Jonas, MD, PhD

While the expanding arsenal of therapies available for patients with AML allows practitioners to further hone treatment and individualize care, the complexity of treatment decision-making requires careful consideration of potential risks and benefits of each treatment option. This real-world, case-based program will provide a format for community hematology-oncologists to hear current updates on the latest targeted therapies in AML and engage in pointed, practical discussions on how to best integrate these data into current and local AML treatment paradigms.

Host: Gerald Watts, MD, PhD

There is a high unmet need for patients with persistent chylomicronemia. Plozasiran (ARO-APOC3) is an investigational drug that is being evaluated for these patients. Professor Gerald Watts shares the outcomes of the PALISADE trial, in which the efficacy and safety of plozasiran was examined in patients with familial chylomicronemia syndrome.

Host: Matthew S. Davids, MD, MMSc

This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and reveals crucial practice gaps. Key challenges include managing poor treatment responses and patient health deterioration, necessitating therapies that extend survival and improve quality of life. Noncovalent Bruton’s tyrosine kinase inhibitors (ncBTKi) show promise in these cases, but clinicians need updated knowledge on their use, including response rates and management of associated toxicities. Additionally, the evolving landscape of B-cell lymphoma therapies complicates treatment choices, requiring expert guidance on individualized therapy selection and sequencing.